Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression
<b>Aim:</b> The Ovarian Cancer Retrospective European (O'CaRE) study assessed the cumulative impact of high-risk factors on progression-free survival (PFS) and overall survival (OS) following first-line treatment in patients diagnosed with advanced ovarian cancer.<b>Patients & methods:</b> Medical records were collected from five European countries (2014 and 2015). Patients were grouped by number of high-risk factors: stage IV diagnosis, no known <i>BRCA mutation</i>, interval debulking surgery or no surgery, or visible residual disease.<b>Results:</b> Our analysis included 405 patients grouped based on having one (20.4%); two (32.3%); three (33.7%) or four (11.9%) high-risk factors. Increasing cumulative numbers of high-risk factors were associated with numerically shorter PFS and OS.<b>Conclusion:</b> Risk profiles should be carefully considered when planning clinical care.
Authors
- Francesco Raspagliesi (ORCID: https://orcid.org/0000-0001-8953-1657)
- Eleanor McDermott (ORCID: https://orcid.org/0000-0001-6302-4171)
- Jonathan Krell (ORCID: https://orcid.org/0000-0002-9835-9227)
- B. Mascialino (ORCID: https://orcid.org/0000-0003-4154-4728)
- Lars Hanker (ORCID: https://orcid.org/0000-0001-6697-018X)
- Andreas D. Hartkopf (ORCID: https://orcid.org/0000-0003-1227-1118)
- Maria Masvidal
- John McGrane (ORCID: https://orcid.org/0000-0001-9371-3250)
- Danielle Shaw
- Jeanne M. Schilder (ORCID: https://orcid.org/0000-0002-6322-5376)
- Linda Kalilani (ORCID: https://orcid.org/0000-0003-2820-0875)
- Ana Herrero (ORCID: https://orcid.org/0000-0002-0229-137X)
- Whitney York
- Cheng Yeoh
Institutions
- Gynecologic Oncology Group (US)
- Royal Cornwall Hospital Trust (GB)
- Royal Cornwall Hospital (GB)
- Age UK (GB)
- Queen Alexandra Hospital (GB)
- Clatterbridge Cancer Centre NHS Foundation Trust (GB)
- Triangle (US)
- Universitätsklinikum Tübingen (DE)
- University Hospital Münster (DE)
- University Hospital Schleswig-Holstein (DE)
- Sunrise Medical (United States) (US)
- GlaxoSmithKline (United States) (US)
- Hospital Universitario Miguel Servet (ES)
- GlaxoSmithKline (Italy) (IT)
- Hospital Universitari Sant Joan de Reus (ES)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Imperial College London (GB)
- University of Lübeck (DE)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1080/14796694.2024.2402217
- Citations
- 1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.54